EOM 1352: Fri 7 June 2024, 11:36
Media Pack
News

Current Edition

Volume 18, Issue 1
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Regional News

China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series A

China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris ...
13 December 2021 Regional News antibody drugs | ASLAN Pharmaceuticals
Continue Reading →
Regional News

Merck’s reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom

Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond its immuno-onco...
29 September 2021 Regional News Acceleron | immuno-oncology
Continue Reading →
news

Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer

Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that TG02 has passed the in...
20 December 2017 news clinical trial | immuno-oncology
Continue Reading →
news

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigatin...
13 December 2017 news immuno-oncology | mesothelioma
Continue Reading →
Catalyst: 12th January 2026
Quotient

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2026, All Rights Reserved – Powered by Teksyte